Biology Intuition + Protein and Antibody Engineering Expertise = The NGM Advantage
We pursue drug discovery and development through a multi-step process geared toward translating powerful human biology into important new medicines.
Our ‘secret sauce’ involves creating a synergy between two core areas of expertise: experimental biology and protein and antibody engineering.
We start with an unsolved problem, deeply interrogate the underlying biology, identify a compelling target, and then engineer a tailored antibody, protein analog or other biologic to elicit the desired therapeutic response. We derive our edge from our people and intuition born of years of experience of when to follow a promising signal and how to move as quickly as possible to human proof-of-concept.
At NGM, we always start with the biology.
Systematic and empirical interrogation of complex disease-associated biology.
When tackling a problem, we don’t think narrowly, or presume to know the best approach. Instead, we challenge ourselves to see the bigger picture and work diligently and methodically to reveal the best approach.
This involves employing unbiased, systematic interrogation of complex disease-associated biology to uncover novel mechanisms of action and to identify proprietary insights into critical biological processes and pathways demonstrating powerful biological effects.
Versatile, modality-flexible biologics platform to design unique solutions
Leveraging these insights, we deploy our protein and antibody engineering expertise to create highly specific product candidates that are designed to modulate targeted processes and pathways and to boost their therapeutic potential.
We have an unbiased antibody generation approach and use an array of modalities and technologies to optimize the properties of our antibody product candidates and native proteins.
Urgent advancement of therapies to meet unmet needs
We use this combination of interrogating human biology and engineering powerful biologics to discover and develop promising product candidates.
While we are explorers at heart, we never conduct science for the sake of the science. Rather, we seek to move our candidates rapidly into proof-of-concept clinical studies and late-stage development. Our motivation and ultimate goal is to deliver impactful treatments to underserved patients suffering from grievous diseases.
Delivering NGM’s Pipeline
Building a diversified pipeline of products made from scratch, curated through disciplined prioritization
We have built a broad and diversified portfolio of product candidates across multiple therapeutic areas. Each of these products are in various stages of active development. NGM regularly nominates new candidates that compete for our next development slot.
We seek to allocate our capital efficiently and strategically and fund our portfolio based on each program’s merits.
We are constantly evaluating our current and potential future development programs competing for our capital and human resources. We have been diligent in applying strict discipline and thoughtful prioritization to partner, forgo, suspend or advance development activities in order to concentrate our resources on what we consider our most promising therapeutic candidates. As a result, we have a constantly evolving pipeline of potentially impactful drug candidates, all delivered from our highly productive discovery engine.